drugset / Trial / NCT00145522

Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women

NCT00145522

Phase 4 Completed 135 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the effects of continuously combined 17b-estradiol/dydrogesterone in comparison with tibolone on the breast metabolic markers, in particular the total insulin-like growth factor-1 (IGF-1), in postmenopausal women.

Timeline

Start
2005-11
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject 17ß-estradiol Unknown 1 mg
Subject Dydrogesterone Other / unclassified 5 mg
Comparator Tibolone Other / unclassified 2.5 mg

Indications

No indication recorded.